Compare PED & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.2M | 179.7M |
| IPO Year | 2012 | 2019 |
| Metric | PED | BNR |
|---|---|---|
| Price | $13.73 | $9.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 24.0K | 14.5K |
| Earning Date | 05-15-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,751,000.00 | N/A |
| Revenue This Year | $171.75 | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $0.43 | $2.95 |
| 52 Week High | $18.89 | $41.72 |
| Indicator | PED | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 26.76 |
| Support Level | $13.09 | $7.99 |
| Resistance Level | $16.24 | $9.70 |
| Average True Range (ATR) | 0.73 | 1.19 |
| MACD | -0.09 | -0.50 |
| Stochastic Oscillator | 28.23 | 6.57 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.